Progress in prophylactic human papillomavirus (HPV) vaccination in 2016: A literature review (Q38628399)

4 September 2017

title

Progress in prophylactic human papillomavirus (HPV) vaccination in 2016: A literature review (English)

1 reference

4 September 2017

main subject

human papilloma virus

1 reference

human papillomavirus

29 September 2024

Polona J Maver

1 reference

4 September 2017

Mario Poljak

series ordinal

1 reference

4 September 2017

language of work or name

English

0 references

publication date

8 August 2017

1 reference

4 September 2017

1 reference

Risk of female human papillomavirus acquisition associated with first male sex partner

4 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.07.113

Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.07.113

Therapy of human papillomavirus-related disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.07.113

Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.07.113

Cross-protection of the Bivalent Human Papillomavirus (HPV) Vaccine Against Variants of Genetically Related High-Risk HPV Infections.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.07.113

Impact of human papillomavirus (HPV) 16 and 18 vaccination on prevalent infections and rates of cervical lesions after excisional treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.07.113

Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.07.113

Prior human papillomavirus-16/18 AS04-adjuvanted vaccination prevents recurrent high grade cervical intraepithelial neoplasia after definitive surgical therapy: Post-hoc analysis from a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.07.113

Epidemiologic Evaluation of Human Papillomavirus Type Competition and the Potential for Type Replacement Post-Vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.07.113

Cervical Infection With Vaccine-Associated Human Papillomavirus (HPV) Genotypes as a Predictor of Acquisition and Clearance of Other HPV Infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.07.113

Population-Level Effects of Human Papillomavirus Vaccination Programs on Infections with Nonvaccine Genotypes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.07.113

Efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine in Chinese women aged 18-25 years: event-triggered analysis of a randomized controlled trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.07.113

Status of New Vaccine Introduction - Worldwide, September 2016.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.07.113

Impact and Effectiveness of the Quadrivalent Human Papillomavirus Vaccine: A Systematic Review of 10 Years of Real-world Experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.07.113

Prevalence of HPV After Introduction of the Vaccination Program in the United States.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.07.113

Substantial Decline in Vaccine-Type Human Papillomavirus (HPV) Among Vaccinated Young Women During the First 8 Years After HPV Vaccine Introduction in a Community

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.07.113

Continuing reductions in HPV 16/18 in a population with high coverage of bivalent HPV vaccination in England: an ongoing cross-sectional study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.07.113

Human Papillomavirus Prevalence and Herd Immunity after Introduction of Vaccination Program, Scotland, 2009-2013.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.07.113

Evaluation of human papillomavirus type replacement postvaccination must account for diagnostic artifacts: masking of HPV52 by HPV16 in anogenital specimens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.07.113

Impact of partial bivalent HPV vaccination on vaccine-type infection: a population-based analysis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.07.113

Significantly Reduced Genoprevalence of Vaccine-Type HPV-16/18 Infections among Vaccinated Compared to Non-Vaccinated Young Women 5.5 Years after a Bivalent HPV-16/18 Vaccine (Cervarix®) Pilot Project in Uganda

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.07.113

Quadrivalent vaccine-targeted human papillomavirus genotypes in heterosexual men after the Australian female human papillomavirus vaccination programme: a retrospective observational study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.07.113

Ongoing decline in genital warts among young heterosexuals 7 years after the Australian human papillomavirus (HPV) vaccination programme

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.07.113

Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.07.113

Significant Reduction in the Incidence of Genital Warts in Young Men 5 Years into the Danish Human Papillomavirus Vaccination Program for Girls and Women.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.07.113

Trends in genital warts by socioeconomic status after the introduction of the national HPV vaccination program in Australia: analysis of national hospital data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.07.113

Impact of human papillomavirus (HPV) vaccination on HPV 16/18-related prevalence in precancerous cervical lesions

7 January 2021

2 references

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.07.113

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.07.113

inferred from DOI database lookup

7 January 2021

based on heuristic

Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.07.113

Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case-control study nested within a population based screening programme in Australia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.07.113

Reduction of low- and high-grade cervical abnormalities associated with high uptake of the HPV bivalent vaccine in Scotland

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.07.113

Reduction in HPV 16/18-associated high grade cervical lesions following HPV vaccine introduction in the United States - 2008-2012.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.07.113

HPV vaccine impact in Australian women: ready for an HPV-based screening program

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.07.113

Quadrivalent HPV vaccine effectiveness against high-grade cervical lesions by age at vaccination: A population-based study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.07.113

Ecological Association of Human Papillomavirus Vaccination with Cervical Dysplasia Prevalence in the United States, 2007-2014.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.07.113

An Overview of Quadrivalent Human Papillomavirus Vaccine Safety: 2006 to 2015.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.07.113

HPV vaccination crisis in Japan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.07.113

Japan's failure to vaccinate girls against human papillomavirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.07.113

Increasing trends in cervical cancer mortality among young Japanese women below the age of 50 years: an analysis using the Kanagawa population-based Cancer Registry, 1975-2012.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.07.113

Development of an efficient strategy to improve HPV immunization coverage in Japan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.07.113

Quadrivalent HPV vaccine safety review and safety monitoring plans for nine-valent HPV vaccine in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.07.113

Immunogenicity and safety of human papillomavirus (HPV) vaccination in Asian populations from six countries: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.07.113

Safety of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in adolescents aged 12-15 years: Interim analysis of a large community-randomized controlled trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.07.113

Incidence of new-onset autoimmune disease in girls and women with pre-existing autoimmune disease after quadrivalent human papillomavirus vaccination: a cohort study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.07.113

The State of Vaccine Confidence 2016: Global Insights Through a 67-Country Survey

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.07.113

Human papillomavirus vaccines: WHO position paper, October 2014-Recommendations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.07.113

Sustained immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine administered as a two-dose schedule in adolescent girls: Five-year clinical data and modeling predictions from a randomized study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.07.113

Randomized Open Trial Comparing 2-Dose Regimens of the Human Papillomavirus 16/18 AS04-Adjuvanted Vaccine in Girls Aged 9-14 Years Versus a 3-Dose Regimen in Women Aged 15-25 Years.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.07.113

Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.07.113

A Single Human Papillomavirus Vaccine Dose Improves B Cell Memory in Previously Infected Subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.07.113

A 9-Valent HPV Vaccine against Infection and Intraepithelial Neoplasia in Women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.07.113

A Randomized, Double-Blind, Phase III Study of the Immunogenicity and Safety of a 9-Valent Human Papillomavirus L1 Virus-Like Particle Vaccine (V503) Versus Gardasil® in 9-15-Year-Old Girls.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.07.113

Immunogenicity and safety of the 9-valent HPV vaccine in men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.07.113

Immunogenicity and Safety of a 9-Valent HPV Vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.07.113

A phase III clinical study to compare the immunogenicity and safety of the 9-valent and quadrivalent HPV vaccines in men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.07.113

Safety Profile of the 9-Valent HPV Vaccine: A Combined Analysis of 7 Phase III Clinical Trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.07.113

Use of the nonavalent HPV vaccine in individuals previously fully or partially vaccinated with bivalent or quadrivalent HPV vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.07.113

Immunogenicity of the 9-Valent HPV Vaccine Using 2-Dose Regimens in Girls and Boys vs a 3-Dose Regimen in Women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.07.113

The potential impact of prophylactic human papillomavirus vaccination on oropharyngeal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.07.113

Quadrivalent Human Papillomavirus (HPV) Vaccine Induces HPV-Specific Antibodies in the Oral Cavity: Results From the Mid-Adult Male Vaccine Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.07.113

Incident Detection of High-Risk Human Papillomavirus Infections in a Cohort of High-Risk Women Aged 25-65 Years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.07.113

Public Health Benefits of Routine Human Papillomavirus Vaccination for Adults in the Netherlands: A Mathematical Modeling Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.07.113

HPV-FASTER: broadening the scope for prevention of HPV-related cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.07.113

Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.07.113

Experiences and lessons learned from 29 HPV vaccination programs implemented in 19 low and middle-income countries, 2009-2014.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.07.113

Argentina's Successful Implementation Of A National Human Papillomavirus Vaccination Program

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.07.113

Eurogin Roadmap 2015: How has HPV knowledge changed our practice: Vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.07.113

10.1016/J.VACCINE.2017.07.113

7 January 2021

Identifiers

DOI

1 reference

4 September 2017

1 reference